What Was The Reason Behind Ocuphire Pharma (OCUP) Stock Increasing 16% Extended Session?
Following the release of peer-reviewed data, Ocuphire Pharma Inc. (NASDAQ: OCUP) shares were up 16.36% to trade at $2.49 at the time of the most recent check. Who published the data from the OCUP? The good outcomes in patients with night vision disturbances (NVD) from Ocuphire Pharma’s initial Phase 2 research assessing the safety and […]
Why Has The Cellectar Biosciences (CLRB) Stock Price Gained 9.52% In After-Market Session?
Shares of Cellectar Biosciences Inc. (Nasdaq: CLRB) were up 9.52% at $2.30 at the time of the most recent check in after-hours trading following an equity move. What equity decision has CLRB made? The previously announced formal agreements between Cellectar Biosciences (CLRB) and a number of institutional investors (the “Investors”) to buy 3,275,153 shares of […]
How Did The PhaseBio (PHAS) Stock Surge In The Pre-Hours Session, Jumping 21%?
Following the disclosure of its bankruptcy filing, shares of PhaseBio Pharmaceuticals Inc. (NASD: PHAS) were up 21.29% to trade at $0.1709 in pre-market at the last check. What was shared by PHAS? PhaseBio (PHAS) declared yesterday that the company had decided to voluntarily file a petition in the U.S. Bankruptcy Court for the District of […]
What Caused The 17% After-Hours Gain In The Super Micro Computer (SMCI) Stock?
Following the release of preliminary quarterly financials, Super Micro Computer Inc. (NASDAQ: SMCI) shares were up 16.71% to trade at $64.88 at the time of the previous check. What did SMCI disclose? Preliminary financial data for the first quarter of Supermicro’s fiscal year 2023, which concluded on September 30, 2022, was released today by Super […]
What Drove The NeuBase (NBSE) Stock Higher In Extended Trades?
After disclosing a proposal for organizational reorganization, NeuBase Therapeutics Inc. (NASDAQ: NBSE) shares increased 11.85% to $0.3029 on Friday after-hours trading. The NBSE stock lost -9.73% to close the last trading session at $0.27. What has NBSE disclosed? NeuBase (NBSE) disclosed plans to reorganize the business to concentrate on the development of its gene-editing platform. […]
What Is The Reason Behind Innovative Eyewear (LUCY) Stock Skyrocketing 93% Today?
There was no major news for Innovative Eyewear Inc. (Nasdaq: LUCY) at the time of the last check, but the stock was up 92.64% at $3.14 in the current market Friday. LUCY shares closed the previous session at $1.62 and traded 33.57 million shares. LUCY recently experienced what? In a recent announcement, Innovative Eyewear (LUCY) […]
Do You Know Why Color Star (CSCW) Stock Jumped 13% On Monday?
In response to its participation in a major event, Color Star Technology Co. Ltd. (Nasdaq: CSCW) has risen 13.56% to trade at $1.34 as of the last check. CSCW stock closed last trading day at $1.18. In which event has CSCW taken part? The Dubai Future Foundation has invited Color Star Technology (CSCW) to participate […]
How Did The Nautilus (NLS) Stock Rise In After-Hours Last Session?
Shares of Nautilus Inc. (NYSE: NLS) were rising 12.94% to trade at $1.92 in after-hours trade, as the company reviews strategic alternatives. NLS stock gained 1.80% to close the regular session at $1.70. How has NLS been evaluating alternatives? It was announced yesterday that Nautilus (NLS) has launched a comprehensive review of strategic alternatives with […]
On What Basis Did Ventoux (VTAQ) Stock Rise 18% Pre-Hours?
The shares of Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) rose 18.11% pre-hours to $6.00 at the last check after a business combination was announced. Stock prices for VTAQ ended Wednesday’s session at $5.08, down -16.86%. What is the combination move made by VTAQ? The previously announced business combination between Presto Automation Inc. and Ventoux (VTAQ) […]
Why Altimmune (ALT) Stock is Down More Than 40% Today?
The shares of Altimmune Inc. (NASDAQ: ALT) were down by -43.03% to $11.61 at the start of the trading on Wednesday despite the company reporting encouraging clinical study results. ALT closed Tuesday’s session at $20.38, down -0.39%. ALT has announced what? As a result of its 12-week Phase 1b study evaluating pemvidutide1, Altimmune (ALT) today […]
